Literature DB >> 10729149

Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.

R E Jeeninga1, M Hoogenkamp, M Armand-Ugon, M de Baar, K Verhoef, B Berkhout.   

Abstract

The current human immunodeficiency virus type 1 (HIV-1) shows an increasing number of distinct viral subtypes, as well as viruses that are recombinants of at least two subtypes. Although no biological differences have been described so far for viruses that belong to different subtypes, there is considerable sequence variation between the different HIV-1 subtypes. The HIV-1 long terminal repeat (LTR) encodes the transcriptional promoter, and the LTR of subtypes A through G was cloned and analyzed to test if there are subtype-specific differences in gene expression. Sequence analysis demonstrated a unique LTR enhancer-promoter configuration for each subtype. Transcription assays with luciferase reporter constructs showed that all subtype LTRs are functional promoters with a low basal transcriptional activity and a high activity in the presence of the viral Tat transcriptional activator protein. All subtype LTRs responded equally well to the Tat trans activator protein of subtype B. This result suggests that there are no major differences in the mechanism of Tat-mediated trans activation among the subtypes. Nevertheless, subtype-specific differences in the activity of the basal LTR promoter were measured in different cell types. Furthermore, we measured a differential response to tumor necrosis factor alpha treatment, and the induction level correlated with the number of NF-kappaB sites in the respective LTRs, which varies from one (subtype E) to three (subtype C). In general, subtype E was found to encode the most potent LTR, and we therefore inserted the core promoter elements of subtype E in the infectious molecular clone of the LAI isolate (subtype B). This recombinant LAI-E virus exhibited a profound replication advantage compared with the original LAI virus in the SupT1 T-cell line, indicating that subtle differences in LTR promoter activity can have a significant impact on viral replication kinetics. These results suggest that there may be considerable biological differences among the HIV-1 subtypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729149      PMCID: PMC111883          DOI: 10.1128/jvi.74.8.3740-3751.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa.

Authors:  M Cornelissen; R van Den Burg; F Zorgdrager; J Goudsmit
Journal:  J Gen Virol       Date:  2000-02       Impact factor: 3.891

2.  Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.

Authors:  E K Ross; A J Buckler-White; A B Rabson; G Englund; M A Martin
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  More ado about HIV's origins.

Authors:  S Wain-Hobson
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

5.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

6.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

Authors:  M J Selby; E S Bain; P A Luciw; B M Peterlin
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

7.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

9.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

View more
  141 in total

Review 1.  Hostile takeovers: viral appropriation of the NF-kappaB pathway.

Authors:  J Hiscott; H Kwon; P Génin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Functional nuclear topography of transcriptionally inducible extra-chromosomal transgene clusters.

Authors:  Manja Meggendorfer; Claudia Weierich; Horst Wolff; Ruth Brack-Werner; Thomas Cremer
Journal:  Chromosome Res       Date:  2010-06-08       Impact factor: 5.239

3.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.

Authors:  Georgios Pollakis; Almaz Abebe; Aletta Kliphuis; Moustapha I M Chalaby; Margreet Bakker; Yohannes Mengistu; Margreet Brouwer; Jaap Goudsmit; Hanneke Schuitemaker; William A Paxton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Evidence for a base triple in the free HIV-1 TAR RNA.

Authors:  Hendrik Huthoff; Frederic Girard; Sybren S Wijmenga; Ben Berkhout
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

6.  Polybacterial challenge enhances HIV reactivation in latently infected macrophages and dendritic cells.

Authors:  Chifu B Huang; Yelena V Alimova; Samantha Strange; Jeffrey L Ebersole
Journal:  Immunology       Date:  2010-11-12       Impact factor: 7.397

7.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

8.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

9.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

10.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.